Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00381134 · ClinicalTrials.gov registry record · Phase 2
Improving Outcomes in Patients With Kidney Disease Due to Diabetes
A Phase 2 study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT00381134 is a Phase 2 study that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 92 participants.
The verdict
NCT00381134, a Phase 2 study, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
Kidney disease affects about one out of three people with diabetes mellitus, a common medical problem. Treatment of kidney disease with medications that lower blood pressure can slow the kidney disease but there is no known cure. This study is designed to test the hypothesis that certain combination-based blood pressure lowering regimens (of FDA approved medications) are better than single agent-based regimens for lowering blood pressure and further slowing or preventing progression of this incurable disease
Interventions
- DRUG spironolactone 25 mg orally once daily
- DRUG losartan 100 mg orally once daily
- DRUG placebo once orally once daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2003-07 |
| Est. Completion | 2006-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00381134
The ClinicalTrials.gov registry entry for NCT00381134 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which spironolactone 25 mg orally once daily is the first listed.
NCT00381134 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00381134 about?
NCT00381134 is a clinical study titled "Improving Outcomes in Patients With Kidney Disease Due to Diabetes". Kidney disease affects about one out of three people with diabetes mellitus, a common medical problem. Treatment of kidney disease with medications that lower blood pressure can slow the kidney disease but there is no known cure. This study is designed to test the hypothesis that certain combination...
What is the current status of trial NCT00381134?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2003-07. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00381134?
The interventions under investigation include: spironolactone 25 mg orally once daily (DRUG), losartan 100 mg orally once daily (DRUG), placebo once orally once daily (DRUG).
Who is sponsoring clinical trial NCT00381134?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.